Actively Recruiting

Phase Not Applicable
Age: 1Year - 80Years
All Genders
Healthy Volunteers
ID05982119

Gait Analysis, Stair Climbing, and Upper Limb Evaluation in Patients With Muscular Disorders and Control Subjects: The ActiLiège Next Study

Led by Centre Hospitalier Universitaire de Liege · Updated on 2025-05-20

300

Participants Needed

8

Research Sites

N/A

Total Duration

On this page

Sponsors

C

Centre Hospitalier Universitaire de Liege

Lead Sponsor

S

SYSNAV

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are collecting long-term data from patients with various neuromuscular disorders such as Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, and Congenital Muscular Dystrophy, along with healthy control subjects. The goal is to validate digital tools that measure motor function continuously in everyday life using a wearable device. This observational study aims to better understand the natural progression of these conditions through real-life movement data. Participants will wear the ActiMyo/Syde device, which can be worn on the wrist or ankle, or placed on a wheelchair, for varying periods depending on their condition and age. Patients with different muscular disorders wear the device for 1 to 3 months at the start and then periodically for one month every 3 to 12 months. Control subjects also wear the device for one month at inclusion and for another month either 6 or 11 months later. Patients undergo standard clinical assessments every 6 to 12 months, while control subjects have evaluations at baseline and after 12 months. During the study, participants will be evaluated through timed motor tests, strength tests, and gait analysis conducted by neurologists or neuropaediatricians. Control subjects may be recruited remotely and provide data such as age and weight by phone or video calls. The primary measurements include stride velocity, stride length, stair climbing details such as number, speed, and height of stairs climbed, tracked over a three-year period. This study includes regular follow-ups to monitor motor function changes and device adherence.

CONDITIONS

Brief Title

Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study

Who Can Participate

Age: 1Year - 80Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Genetically confirmed diagnosis of DMD, FSHD, DM1, CMT, FKRP mutations, or confirmed CNM by muscle biopsy
  • Ambulatory or transitioning patients for FSHD, DM1, CMT, and CNM
  • DM1 and CMT patients must show sensori-motor signs on exam
  • Age under 20 years for DMD or CNM patients
  • Age 5 to 80 years for FSHD, CMT, and DM1 patients
  • Age over 2 years for FKRP mutation patients
  • Non-ambulant DMD patients must be able to sit in a wheelchair or armchair for at least one hour
  • DMD patients must have at least 6 months of corticosteroid treatment or start at baseline (except under 4 years old)
  • Signed informed consent by patient or guardian
  • Ambulant boys and girls under 20 years old for control subjects
  • Signed informed consent for control subjects
Not Eligible

You will not qualify if you...

  • Severe cognitive disorders limiting exercise understanding
  • Surgery or recent trauma within 6 months affecting limbs (for ambulant patients or controls)
  • Chronic or acute neurological, endocrine, infectious, allergic, or inflammatory disease within 3 weeks before inclusion
  • Participation in another interventional clinical trial
  • DMD patients in transition not on corticosteroids
  • Elite athletes at national level (controls)
  • Orthopedic, neuromuscular, or neurological condition affecting walking gait (controls)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) to assess eligibility

Implementation

Duration - Up to 3 years

Participants will wear the ActiMyo/Syde device for periods ranging from one to three months at baseline depending on disease group or control status, followed by additional wearing periods every 3 to 12 months depending on age and disease group.

Device wearing periods include 1 to 3 months at baseline and 1 month every 3 to 12 months; assessments occur at baseline and every 6 to 12 months for patients, and at inclusion and 12 months for control subjects

Monitoring

Duration - Up to 3 years

Participants undergo standardized assessments including timed tests, motor function tests, and strength tests at baseline and follow-up visits occurring every 6 to 12 months depending on age and disease group. Control subjects have remote data collection by phone or video conference every 6 months for 3 years.

Assessments every 6 to 12 months for patients; remote data collection every 6 months for controls

Trial Site Locations

Total: 8 locations

1

CHR de la Citadelle

Liège, Belgium, 4000

Actively Recruiting

2

Fakultni nemocnice v Motole

Prague, Czechia

Active, Not Recruiting

3

Galaa Military Medical Complex

Cairo, Egypt

Active, Not Recruiting

4

Semmelweis University 2nd Department of Paediatrics

Budapest, Hungary

Active, Not Recruiting

5

Warsaw Medical University Hospital, Department of Neurology

Warsaw, Poland

Active, Not Recruiting

6

Pediatric Neurology Clinic, Clinical Hospital of Psychiatry "Prof. Dr. Al. Obregia"

Bucharest, Romania, 041914

Actively Recruiting

7

National Clinical Hospital for Children Neurohabilitation "Dr Nicolae Robanescu"

Bucharest, Romania

Active, Not Recruiting

8

University Children's Hospital, Department for Pediatric Neurology

Ljubljana, Slovenia

Active, Not Recruiting

Loading map...

Research Team

C

Charline DUBOIS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Similar Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Mult...

Myotonic Dystrophy 1

Actively Recruiting

8 locations

A Phase 1/2, Open-Label, Dose Escalation Study to Assess the...

Duchenne Muscular Dystrophy

Actively Recruiting

8 locations

A Registered Cohort Study on Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here